Evidence map›Paper›PMID 41606605›Full record

ArticleRespiratory research2026

Solasonine inhibits NSCLC malignant progression by regulating SLC7A11 ubiquitination degradation and inducing ferroptosis.

Yuhan Wang, Xiaodan Li, Chuanqiang Zhou, Minxuan Qian, Zhangyan Zou, Wenhui Yang, Nodem Saha Joel Wilfred, Gang Huang, Xianghuai Xu, Fengfeng Xue and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuhan Wang *Shanghai Key Laboratory of Molecular Imaging, Pudong Gongli Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Xiaodan Li *Shanghai Key Laboratory of Molecular Imaging, Pudong Gongli Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Chuanqiang ZhouShanghai Key Laboratory of Molecular Imaging, Pudong Gongli Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Minxuan QianShanghai Key Laboratory of Molecular Imaging, Pudong Gongli Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Zhangyan ZouShanghai Key Laboratory of Molecular Imaging, Pudong Gongli Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Wenhui YangShanghai Key Laboratory of Molecular Imaging, Pudong Gongli Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Nodem Saha Joel WilfredShanghai Key Laboratory of Molecular Imaging, Pudong Gongli Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Gang HuangShanghai Key Laboratory of Molecular Imaging, Pudong Gongli Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China. huanggang502@sumhs.edu.cn.
Xianghuai XuDepartment of Pulmonary and Critical Care Medicine, School of Medicine, Tongji Hospital, Tongji University, Shanghai, 200065, China. 05849@tongji.edu.cn.
Fengfeng XueShanghai Key Laboratory of Molecular Imaging, Pudong Gongli Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China. xuefengfeng@msn.com.
Mingming JinShanghai Key Laboratory of Molecular Imaging, Pudong Gongli Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China. asdjinmingming@126.com.

Funding

National Key Research and Development Program of China 2020YFA0909000National Natural Science Foundation of China 52103171National Natural Science Foundation of China 82127807Shanghai Key Laboratory of Molecular Imaging 18DZ2260400Shanghai Municipal Health Commission Medical New Technology research and Transformation Seed Program Project Plan Assignment 2024ZZ2056Shanghai "Science and Technology Innovation Action Plan" Natural Science und Project 24ZR1429400Shanghai Science and Technology program 23010502600
6 · The paper itself

Abstract

background and purposeThis study responds to the pressing need for novel therapeutic strategies to address key challenges in non-small cell lung cancer (NSCLC) treatment. It explores effective traditional Chinese medicine, investigates its molecular mechanism, and pursues the modernization of traditional Chinese medicine. The current research investigated how Solasonine (SS) extracted from Solanum nigrum L. may counter NSCLC by activating the ferroptosis pathway, while also elucidating the fundamental molecular mechanisms involved.

methodsProliferation (CCK8) and metastasis (wound healing) of A549/HCC1833 cells were assessed. Reactive oxygen species (ROS) production, proteomic sequencing, co-immunoprecipitation (Co-IP), and molecular docking mechanisms of the SS treatment group were analyzed. SLC7A11 regulation was evaluated using ferroptosis inhibitors and by ubiquitination assays. SS efficacy was tested in a subcutaneous/lung metastasis nude mouse model.

resultsSS suppressed NSCLC proliferation/metastasis by inducing ferroptosis. Proteomics revealed SS downregulated ferroptosis-related proteins and SLC7A11. SS promoted SLC7A11 ubiquitination/degradation via USP10/TRIM25 interactions, confirmed by Co-IP/docking. In vitro/vivo, SS increased ROS, inhibited tumor growth/metastasis, and activated ferroptosis pathways (reduced SLC7A11/GPX4/GSR/GSS). Immunohistochemistry confirmed the presence of ferroptosis markers in tumors.

conclusionSS triggers ferroptosis in NSCLC by disrupting USP10/TRIM25-mediated SLC7A11 stability. This study proposes a novel treatment strategy for NSCLC with a traditional Chinese medicine monomer.

Indexed as

Amino Acid Transport System y+Carcinoma, Non-Small-Cell LungDisease ProgressionFerroptosisLung NeoplasmsUbiquitinationA549 CellsAnimalsCell Line, TumorCell ProliferationHumansMiceMice, Inbred BALB CMice, NudeXenograft Model Antitumor AssaysAmino Acid Transport System y+SLC7A11 protein, humanFerroptosisNon-small cell lung cancer (NSCLC)SolasonineTraditional Chinese MedicineUbiquitination

Identifiers

PMID41606605
PMCPMC12918229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.